Rani Therapeutics Holdings (RANI) EBT (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly EBT of -$10.4 million for Q1 2026, up 18.72% year-over-year from -$8.7 million in Q1 2025, and down 20.02% quarter-over-quarter from -$8.6 million in Q4 2025.
Rani Therapeutics Holdings (RANI) EBT (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' EBT history runs 7 years deep, the most recent figure standing at -$10.4 million for Q1 2026.
- In Q1 2026, EBT rose 18.72% year-over-year to -$10.4 million; the TTM figure through Mar 2026 stood at -$42.2 million (up 25.13% YoY), while the FY2025 annual figure was -$116.5 million, down 105.96% from the prior year.
- EBT for Q1 2026 stood at -$10.4 million, down from -$8.6 million in the prior quarter.
- The five-year high for EBT was -$8.6 million in Q4 2025, with the low at -$18.7 million in Q2 2023.
- The 5-year median for EBT is -$14.1 million (2023), against an average of -$14.4 million.
- Peak annual rise in EBT reached 43.08% in 2022, while the deepest fall reached 188.33% in 2022.
- Rani Therapeutics Holdings' EBT stood at -$17.4 million in 2022, then climbed by 19.15% to -$14.1 million in 2023, then gained by 13.42% to -$12.2 million in 2024, then rose by 29.11% to -$8.6 million in 2025, then retreated by 20.02% to -$10.4 million in 2026.
- Business Quant data shows RANI's EBT at -$10.4 million in Q1 2026, -$8.6 million in Q4 2025, and -$12.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Rani Therapeutics Holdings | 160.33 Mn | 160.33 Mn | - | -8.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.46 Mn |
| Mar 31, 2026 | -10.35 Mn |
| Dec 31, 2025 | -8.63 Mn |
| Sep 30, 2025 | -11.96 Mn |
| Jun 30, 2025 | -11.30 Mn |
| Mar 31, 2025 | -12.74 Mn |
| Dec 31, 2024 | -12.17 Mn |
| Sep 30, 2024 | -18.05 Mn |
| Jun 30, 2024 | -13.46 Mn |
| Mar 31, 2024 | -14.78 Mn |
| Dec 31, 2023 | -14.06 Mn |
| Sep 30, 2023 | -18.33 Mn |
| Jun 30, 2023 | -18.66 Mn |
| Mar 31, 2023 | -16.83 Mn |
| Dec 31, 2022 | -17.38 Mn |
| Sep 30, 2022 | -16.32 Mn |
| Jun 30, 2022 | -15.81 Mn |
| Mar 31, 2022 | -13.77 Mn |
| Dec 31, 2021 | -13.35 Mn |
| Sep 30, 2021 | -28.66 Mn |